Programs & products

Phase 2 expansion cohort data supports ongoing Phase 3 trial Innate Pharma SA (Euronext Paris: IPH – ISIN: FR0010331421; Nasdaq: IPHA) (“ Innate ” or the “ Company ”) today announced that it will...

Priority Medicines (PRIME) designation supports the potential for lacutamab to benefit Sézary Syndrome patients in need of new treatment options Innate Pharma SA (Euronext Paris: IPH – ISIN...

Milestone payment further bolsters Innate’s cash position INTERLINK-1 represents first Phase 3 study examining IO approach in R/M SCCHN patients who have been treated with a platinum-based therapy and...

Innate resumed enrollment of lacutamab TELLOMAK Phase 2 clinical trial for patients with Sézary syndrome and mycosis fungoides Monalizumab Phase 3 study expected to initiate in the second half of 2020...

Innate Pharma to re-activate TELLOMAK trial in the US New GMP-certified batch has been successfully manufactured Conference call to be held today on the lacutamab clinical trial program Innate Pharma...

Phase II expansion cohort of “IO-pretreated patients” demonstrates 20% overall response rate Data confirm previous preliminary efficacy data seen in this subpopulation Innate Pharma SA (Euronext Paris...

Anti-CD39 monoclonal antibody, IPH5201, advances to first-in-human clinical trial; first molecule from Innate/AstraZeneca expanded collaboration progressing to the clinic Innate Pharma SA (Euronext...

Innate Pharma SA (Euronext Paris: IPH – ISIN: FR0010331421; Nasdaq: IPHA) (“ Innate ” or the “ Company ”) today announced that the French National Agency for Medicines and Health Product Safety (ANSM)...

Innate Pharma SA (Euronext Paris: IPH – ISIN: FR0010331421; Nasdaq: IPHA) (“ Innate ” or the “ Company ”) today announced a regulatory update regarding its TELLOMAK Phase II trial, evaluating the...

Innate Pharma SA (Euronext Paris: IPH – ISIN: FR0010331421; Nasdaq: IPHA) (“ Innate ” or the “ Company ”) today announced that the European Medicines Agency (EMA) has accepted the Marketing...